Citi raised the firm’s price target on Guardant Health (GH) to $100 from $65 and keeps a Buy rating on the shares. The firm says the company’s momentum continues following the “beat and raise” Q3 print.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH: